Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-23T16:33:56.893Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmacogenetics and antidepressant treatment outcomes in pregnancy: a Danish-population based study

Published online by Cambridge University Press:  01 September 2022

M. Mushtaq ,
K. Ishtiak-Ahmed ,
J. Thirstrup  and
C. Gasse
M. Mushtaq*
Affiliation:
Aarhus University Hospital Psychiatry, Department Of Affective Disorders, Aarhus N, Denmark
K. Ishtiak-Ahmed
Affiliation:
Aarhus University Hospital Psychiatry, Department Of Affective Disorders, Aarhus N, Denmark Aarhus University, Department Of Clinical Medicine, Aarhus N, Denmark
J. Thirstrup
Affiliation:
Aarhus University Hospital Psychiatry, Department Of Affective Disorders, Aarhus N, Denmark Aarhus University, Department Of Clinical Medicine, Aarhus N, Denmark
C. Gasse
Affiliation:
Aarhus University Hospital Psychiatry, Department Of Affective Disorders, Aarhus N, Denmark Aarhus University, Department Of Clinical Medicine, Aarhus N, Denmark
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Depression in pregnancy is common and often requires treatment with antidepressant drugs. Most antidepressants are metabolized by the cytochrome P450 system (CYP), in particular CYP2C19 and -2D6, both of which are genetically polymorphic. Additionally, the activity of these enzymes is altered during pregnancy.

Objectives

To investigate pharmacogenetic variability regarding CYP2C19 and -2D6 in pregnant users of antidepressants and treatment outcomes.

Methods

The study population comprises all women born between 1981-1999, who gave birth to at least one child before December 2015 identified from the large Danish population-based iPSYCH2012 case-cohort study sample linked to information on genetic variants, prescription drug use and outcome data. Pharmacogenetic genotypes and phenotypes of CYP2C19 and CYP2D6 will be categorized into poor, (PM), intermediate, (IM), extensive, (EM), rapid (RM) and ultra-rapid metabolizers (RM) using array-based SNP information. Antidepressant drug use and comedication during pregnancy will be assessed based on prescription data. Outcomes include treatment discontinuation, switching and psychiatric hospitalizations. Cox regression analysis will be performed to estimate the hazard ratios comparing the rates of the different outcomes in people with different phenotypes, compared with EM adjusted for a number of confounding factors.

Results

Based on previous research we will be able to identify approximately 6531 pregnant women with a psychiatric history. Among those, we estimate to find 14 PM, 161 IM, 285 EM, 168 RM and 25 UM of CYP2C19, and 27 PM, 218 IM and 408 EM of CYP2D6. Exposure to antidepressants is estimated at 10%.

Conclusions

We expect to be able to present the results at the conference.

Disclosure

No significant relationships.

Keywords

DepressionAntidepressantspharmacogeneticsPregnancy
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S104
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.